188 results about "Extracellular matrix" patented technology

An endoluminal prosthesis is provided for restricting fluid flow in a lumen. The endoluminal prosthesis has a tubular graft having a flexible body with at least one stent coupled thereto. The endoluminal prosthesis also includes a prosthetic valve coupled to the inside the tubular graft. The prosthetic valve can be made of a synthetic or an organic material, such as an extracellular matrix, and can operate to limit fluid flow in one direction, but allow fluid flow in the other direction.

Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and / or repair damaged heart tissue.

Disclosed is a device for sticking a plurality of cells to one basement in sequential arrays, which is characterized in that the upper surface of the basement is sequentially plated with a titanium adhesion layer, a golden layer, bands of mercaptan hydrophobic monolayer and bands of mercaptan hydrophilic monolayer, and the bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer are parallel attached on the golden layer at intervals; the lower surface is provided with a second polydimethylsiloxane seal of a micro-groove unit; the micro-groove unit is composed of three parallel linear grooves; the ends of the grooves are provided with vertical through holes communicated with the grooves; the lower surface of the seal is coated on the surface of the basement with parallel bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer; the linear grooves are perpendicular to the bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer; and the golden surface of the basement is formed into a zone for the cells to be stuck on selectively. Substances (such as protein solution of the extra cellular matrix and polylysine solution, etc.), which facilitate the cells to be stuck, are injected into microflow pipes; after the cells are stuck selectively, different cell suspensions are injected into different pipes, and the cells are only stuck on the surfaces of the hydrophobic monolayer; then the seal is taken off, a plurality of different cell arrays are sequentially stuck on the basement.